Skip to content

Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension

Hypertonic Saline and Terlipressin Linked To an Early Goal-Driven Protocol for Septic Shock or Sepsis-Associated Hypotension: A Pilot Trial (HYSATESS)

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01271114
Acronym
HYSATESS-p
Enrollment
21
Registered
2011-01-06
Start date
2012-06-30
Completion date
2013-12-31
Last updated
2014-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated Hypotension, Septic Shock

Brief summary

In hypotensive septic patients with controlled source, an hemodynamic management protocol including hypertonic saline (HS)and terlipressin improves MOD (Multiple Organ Dysfunction) Score by at least 3 points compared to the use of physiologic saline and norepinephrine. The appropriate design for this trial would be factorial. For the time being, will consider de intervention as a whole unit for this pilot study. In the future an appropriately sized factorial multicentric study shall be necessary. Other goals of the pilot study: 1. HS restores preload parameters adequately 2. HS associated with terlipressin normalizes blood pressure in septic shock 3. HS associated with terlipressin maintains plasma sodium levels 130-155mEq/L 4. There is an inverse relationship between plasma sodium and procalcitonin levels 5. HS increases plasma levels of vasopressin (AVP) 6. HS rises levels of cortisol but not of adrenocorticotropic hormone (ACTH)

Interventions

DRUGHypertonic Saline and Terlipressin

Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg

DRUGNormal saline and norepinephrine

Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg

Sponsors

University of Castilla-La Mancha
CollaboratorOTHER
Hospital General de Ciudad Real
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Criteria of SIRS: at least 2 of 4: * Temperature \> 38 °c or \< 36 ° C * More than 90 bpm heart rate * Respiratory rate more than 20rpm or PaCO2 less than 32 mm Hg or patient in mechanical ventilation * Less than 4000/ mm³ or more than 12000/mm³, or more than 10% leukocyte bands (immature) * Septic source known demonstrated (or at least of high probability) and controlled (if it is controllable) * Hematocrit 25% or higher and/or hemoglobin 8 g/dL or higher. If necessary, transfuse RBCs to meet this criteria * MAP less than 70 mm Hg. Note there is no requirement for adequate preload evidence

Exclusion criteria

* Hypernatremia at base-line of 155 mEq/L or greater Hyponatremia at base-line less than 130mEq / L * Prior endocrine disease affecting to the adrenal-pituitary axis. * Intracranial Hypertension, brain tumor, seizures, head trauma * Coronary Artery Disease active over the past year; or evidence of myocardium at risk by exercise stress test, pharmacological or positive gammagraphy last year without intervention * Pregnancy * Liver disease Child C, End-Stage-Renal-Disease * Under the age of 18 * Patients with order do not resuscitate or with minimal chances to survive

Design outcomes

Primary

MeasureTime frame
MOD (Multiple Organ Dysfunction) Scoredaily, as long as the patient stays in the ICU

Secondary

MeasureTime frame
Hypertonic Saline associated with terlipressin maintains plasma sodium levels 130-155mEq/LAs long as Hypertonic saline plus terlipressin are in use and one week later
There is an inverse relationship between plasma sodium and plasma procalcitonin levels measured by a negative Pearson coefficientAs long as the patient stays in the ICU
Hypertonic Saline restores IV fluid response parameters (Pulse Pressure Variation or Systolic Volume Variation) adequatelyFirst 48 hours
Hypertonic Saline boluses increases plasma levels of vasopressin (AVP)First week in ICU
Hypertonic Saline use rises levels of cortisol but not of adrenocorticotropic hormone (ACTH)First week in ICU
Hypertonic Saline associated with terlipressin normalizes blood pressure in septic shockFirst 48 hours

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026